Access to durvalumab for lung cancer is cost-prohibitive

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, FDA has approved two KRAS inhibitors to treat patients with specific KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.

October 02, 2026

Vol.52 No.36

Perspective

When did stage 3B lung cancer become “early stage”?

My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial.

September 25, 2026

Vol.52 No.35

Clinical Roundup

EGFR mutation linked to dramatically increased lung cancer risk

A rare inherited mutation in the Epidermal Growth Factor Receptor gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds

Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Hansoh Pharmaceutical Group announced positive overall survival data from ARTEMIS-008, its pivotal phase III trial in China, evaluating the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) versus topotecan in patients with relapsed small cell lung cancer whose disease progressed following platinum-based first-line therapy.

September 18, 2026

Vol.52 No.34

Access to durvalumab for lung cancer is cost-prohibitive

YOU MAY BE INTERESTED IN

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

When did stage 3B lung cancer become “early stage”?

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

EGFR mutation linked to dramatically increased lung cancer risk

Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Renew today!

Subscriber content

Never miss an issue!

Login